Shamburg News · 8-K filed Nov 13, 2026, 8:54 PM EST

CorMedix Hosts Q3 2026 Earnings Call; Discusses Proposed Heron Therapeutics Asset Acquisition

CRMD · CorMedix Inc.

  • Earnings
  • Acquisition
  • Reg FD disclosure
  • Materiality: high

On November 12, 2026, CorMedix hosted a conference call to discuss its third quarter 2026 results, and a transcript was furnished as Exhibit 99.1 under Item 7.01. On the call, management reported third quarter consolidated revenue of $54.5 million and adjusted EBITDA of $3.1 million, a GAAP net loss of $14.7 million or $0.19 per share, and cash of $355.2 million. The call also covered the proposed acquisition of substantially all assets of Heron Therapeutics, the deferral of 2027 DefenCath guidance, and reaffirmed 2026 revenue guidance of $325 million to $345 million.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001213900-26-120016.

Written from the filing by Shamburg Markets. Figures are as reported by the company.